SNC116 is named as a drug or biological intervention in 2 clinical trials in our China trial register, none of which are currently recruiting. Lead sponsors include Shanghai Simnova Biotechnology Co.,Ltd. (1) and The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1). Registered phase: Phase EARLY_PHASE1. Conditions studied include B-cell Acute Lymphoblastic Leukemia; Systemic Lupus Erythematosus.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07748156 | SNC116 Therapy for Refractory Systemic Lupus Erythematosus (ClinicalTrials.gov ↗) Systemic Lupus Erythematosus |
Phase EARLY_PHASE1 | Not yet open |
| NCT07830238 | SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (ClinicalTrials.gov ↗) B-cell Acute Lymphoblastic Leukemia |
Phase EARLY_PHASE1 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| B-cell Acute Lymphoblastic Leukemia | 1 |
| Systemic Lupus Erythematosus | 1 |
| Lead sponsor | Trials |
|---|---|
| Shanghai Simnova Biotechnology Co.,Ltd. | 1 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 1 |
| Register | SNC116 trials |
|---|---|
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how SNC116 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists SNC116 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.